Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BYSTOLIC vs TRULANCE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bystolic (nebivolol) is a beta-1 selective adrenergic receptor antagonist with additional nitric oxide-mediated vasodilatory effects. It decreases heart rate, myocardial contractility, and blood pressure by blocking beta-1 receptors in the heart and kidney, and enhances nitric oxide release from vascular endothelium via beta-3 receptor activation.
Guanylate cyclase-C receptor agonist; increases intracellular c GMP, leading to chloride and water secretion into intestinal lumen and accelerated transit.
Hypertension: treatment of hypertension, alone or in combination with other antihypertensives,Heart failure: stable mild to moderate chronic heart failure in addition to standard therapy (off-label)
Chronic idiopathic constipation (CIC),Irritable bowel syndrome with constipation (IBS-C)
Oral: 5 mg once daily; may increase at 2-week intervals to 10 mg, 20 mg, 40 mg; maximum 40 mg/day.
3 mg orally once daily.
Terminal elimination half-life: 10-12 hours; allows once-daily dosing in most patients; steady-state achieved in 3-5 days
Terminal elimination half-life is approximately 16 hours, supporting once-daily dosing.
Extensively metabolized via CYP2D6 and glucuronidation. Active metabolites are formed, including desmethylnebivolol. Genetic polymorphisms in CYP2D6 affect drug levels.
Metabolized by hydrolysis and reduction, not via cytochrome P450; converted to active and inactive metabolites.
Renal: 38% unchanged; hepatic metabolism: extensive; fecal: minor; total renal clearance accounts for 30-50% of dose
Primarily excreted in feces as unchanged drug (approximately 60%) and as metabolites; renal excretion is minimal (<3%).
25-30% bound to albumin (alpha-1-acid glycoprotein not significant)
Approximately 95% bound to plasma proteins, primarily albumin.
Vd: ~2.5 L/kg (extensive extravascular distribution, consistent with moderate lipophilicity)
Volume of distribution is approximately 2.3 L/kg, indicating extensive tissue distribution.
Oral: 33% (due to first-pass metabolism; food does not significantly affect AUC; low variability)
Absolute bioavailability is approximately 19% after oral administration due to first-pass metabolism.
No adjustment for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), initial dose 2.5 mg once daily; titrate cautiously; maximum 20 mg/day.
No dose adjustment required for any degree of renal impairment, including end-stage renal disease.
Child-Pugh Class A: initial 2.5 mg once daily; increase cautiously; maximum 20 mg/day. Child-Pugh Class B: initial 2.5 mg once daily; increase cautiously; maximum 10 mg/day. Child-Pugh Class C: not recommended.
No dose adjustment required for mild or moderate hepatic impairment (Child-Pugh class A or B). Not studied in severe hepatic impairment (Child-Pugh class C); use not recommended.
Not established; safety and efficacy not evaluated in pediatric patients.
Safety and efficacy not established in pediatric patients below 18 years of age.
Initial dose 2.5 mg once daily; titrate slowly; maximum 40 mg/day. Monitor heart rate and blood pressure closely.
No specific dose adjustment recommended; however, consider potential increased sensitivity and monitor renal function due to age-related decline.
No FDA black box warning.
Not applicable.
Abrupt discontinuation may exacerbate angina or myocardial infarction in coronary artery disease,May mask signs of hyperthyroidism,Caution in peripheral vascular disease and Raynaud's phenomenon,May cause bronchospasm in patients with asthma or COPD,Caution in patients with diabetes mellitus due to masking of hypoglycemia,May cause bradycardia or heart block,Caution in renal or hepatic impairment
Risk of diarrhea, sometimes severe; avoid in patients with suspected or known mechanical gastrointestinal obstruction; caution in patients with severe hepatic impairment.
Sinus bradycardia,Second- or third-degree heart block,Cardiogenic shock,Decompensated heart failure,Sick sinus syndrome (unless pacemaker present),Severe hepatic impairment,Hypersensitivity to nebivolol or any component
Known or suspected mechanical gastrointestinal obstruction; pediatric patients <2 years of age; hypersensitivity to linaclotide or any component of the formulation.
Avoid alcohol as it may increase blood pressure-lowering effect. No significant food interactions; however, grapefruit juice may slightly increase nebivolol levels but not clinically relevant.
No significant food interactions; can be taken with or without food.
First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: Beta-blockers may cause fetal bradycardia, intrauterine growth restriction, and neonatal hypoglycemia; risk is dose-dependent.
No adequate and well-controlled studies in pregnant women. Animal studies show no evidence of harm at clinically relevant exposures. Risk cannot be ruled out; use only if clearly needed.
Nebivolol is excreted into breast milk; M/P ratio not established. Limited human data; use with caution in nursing mothers due to potential for infant bradycardia and hypotension.
No data on presence in human milk, effects on breastfed infant, or milk production. Exercise caution; consider developmental and health benefits of breastfeeding alongside maternal need for TRULANCE.
No specific dose adjustments established; use lowest effective dose; increase monitoring for maternal hypotension and fetal bradycardia; consider discontinuation if fetal distress occurs.
No dose adjustment recommended based on pharmacokinetic changes; however, clinical data are lacking.
Bystolic (nebivolol) is a beta-1 selective blocker with nitric oxide-mediated vasodilation, resulting in lower incidence of fatigue and sexual dysfunction compared to other beta-blockers. No dose adjustment needed in mild to moderate hepatic impairment but contraindicated in severe impairment. Maximum antihypertensive effect may take 2 weeks. Use caution in patients with asthma or COPD due to beta-1 selectivity may be lost at higher doses. Do not discontinue abruptly; taper over 1-2 weeks.
Trulance (plecanatide) is a guanylate cyclase-C agonist indicated for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). It increases intestinal fluid and transit. Avoid use in patients younger than 6 years due to risk of severe dehydration. Dose is 3 mg once daily; no adjustment for renal or hepatic impairment. Onset may take days to weeks. Titration not needed.
Take once daily at the same time each day, with or without food.,Do not stop taking suddenly as this may cause chest pain or heart attack; consult your doctor for gradual dose reduction.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how you react.,Notify your doctor if you experience slow heartbeat, shortness of breath, swelling of feet or legs, or signs of allergic reaction.,Inform all healthcare providers that you take this medication, especially before surgery or any procedure involving anesthesia.
Take Trulance once daily with or without food.,Swallow tablet whole; do not crush or chew.,Diarrhea is the most common side effect; report severe or persistent diarrhea.,May cause dehydration; drink adequate fluids.,Not recommended in children under 6 years.,Store at room temperature; keep out of reach of children.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BYSTOLIC vs TRULANCE, answered by our medical review team.
BYSTOLIC is a Beta Blocker that works by Bystolic (nebivolol) is a beta-1 selective adrenergic receptor antagonist with additional nitric oxide-mediated vasodilatory effects. It decreases heart rate, myocardial contractility, and blood pressure by blocking beta-1 receptors in the heart and kidney, and enhances nitric oxide release from vascular endothelium via beta-3 receptor activation.. TRULANCE is a Guanylate Cyclase-C Agonist that works by Guanylate cyclase-C receptor agonist; increases intracellular c GMP, leading to chloride and water secretion into intestinal lumen and accelerated transit.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BYSTOLIC and TRULANCE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BYSTOLIC is: Oral: 5 mg once daily; may increase at 2-week intervals to 10 mg, 20 mg, 40 mg; maximum 40 mg/day.. The standard adult dose of TRULANCE is: 3 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BYSTOLIC and TRULANCE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BYSTOLIC is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: Beta-blockers may cause fetal bradycardia, intraute. TRULANCE is classified as Category C. No adequate and well-controlled studies in pregnant women. Animal studies show no evidence of harm at clinically relevant exposures. Risk cannot be ruled out; use only if clearly n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.